A prognostically relevant miRNA signature for epithelial ovarian cancer

The Lancet Oncology

Volumn 17, Issue 8, 2016, Pages 1032-1033

  Cramer, Daniel W ^a,b,c   Elias, Kevin M ^a,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; DISEASE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; MOLECULAR PATHOLOGY; NOTE; OVARY CARCINOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM; OVARY TUMOR;

FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84995950931     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30149-8     Document Type: Note

References (10)

1. 1 Keegan, TH, Ries, LA, Barr, RD, et al. Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. Cancer 122 (2016), 1009–1016.
2. 2 Verhaak, RG, Tamayo, P, Yang, JY, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123 (2013), 517–525.
3. 3 Alexander, RP, Fang, G, Rozowsky, J, Snyder, M, Gerstein, MB, Annotating non-coding regions of the genome. Nat Rev Genet 11 (2010), 559–571.
4. 4 Bartel, DP, MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004), 281–297.
5. 5 Pasquinelli, AE, MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet 13 (2012), 271–282.
6. 6 Mitchell, PS, Parkin, RK, Kroh, EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105 (2008), 10513–10518.
7. 7 Bagnoli, M, Canevari, S, Califano, D, et al., for the Multicentre Italian Trials in Ovarian cancer (MITO) translational group. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncol, 2016 published online July 8. http://dx.doi.org/10.1016/S1470-2045(16)30108-5.
8. 8 Sgroi, DC, Sestak, I, Cuzick, J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 14 (2013), 1067–1076.
9. 9 Pignata, S, Scambia, G, Ferrandina, G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 29 (2011), 3628–3635.
10. 10 Griffiths-Jones, S, Grocock, RJ, van Dongen, S, Bateman, A, Enright, AJ, miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34 (2006), D140–D144.